Sage Therapeutics Inc Expected To Post A Loss Of $1.65 A Share: Earnings Preview

Sage Therapeutics

23/04/2024 16:27

* SAGE Therapeutics Inc  SAGE.OQ   SAGE.O  is expected
to show a
rise in quarterly revenue when it reports  results on April 25
for the period ending March 31 2024
    * The Cambridge Massachusetts-based  company is expected to
report
a 71.8% increase in revenue to $5.658 million from $3.29 million
a year ago, according to the mean estimate from 17 analysts,
based on LSEG data.
    * ​LSEG's mean analyst estimate for SAGE Therapeutics Inc is
for a
loss of $1.65 per share. 
    * The current average analyst rating on the shares is "hold"
and
the breakdown of recommendations is 4 "strong buy" or "buy," 16
"hold" and 1 "sell" or "strong sell."  
    * The mean earnings estimate of analysts had fallen by
about 3.7%
in the last three months. ​
    * Wall Street's median 12-month price target for SAGE
Therapeutics
Inc is $22.00​, above​ its last closing price of $12.89. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %
               E®                               MISSED  
 Dec. 31 2023  -1.65       -1.28      -1.80     Missed  -40.9
 Sep. 30 2023  -2.76       -2.73      -3.37     Missed  -23.4
 Jun. 30 2023  -2.56       -2.55      -2.68     Missed  -4.9​
 Mar. 31 2023  -2.47       -2.50      -2.46     Beat    1.4
 ​​Dec.        -2.41       -2.39      -2.47     Missed  -3.5
 31 2022                                                
 Sep. 30 2022  -2.24       -2.21      -2.31     Missed  -4.7​
 Jun. 30 2022  -2.17       -2.15      -2.13     Beat    1
 Mar. 31 2022  -2.05       -2.04      -2.07     Missed  -1.6
 This summary was machine generated April 23 at 15:27 GMT.  All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)